SUPPLEMENT

FY2025 — Additional analyst information

FY2025PDF · 23 pages2.0 MB
This pack has been prepared to aid discussion and provide further
supplementary information only and has not been subject to an
external review or audit

-- 1 of 23 --

CUSTOMERS PER ENTITY
Life Policyholders
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Individual 453,418 450,866 449,211 449,300 447,690 449,130 449,020 449,378 448,313 445,813 446,713 452,561 446,475
Invest
Invest - DRO 137,297 137,441 137,503 137,718 137,189 135,819 134,721 133,741 132,817 131,244 129,606 127,831 124,135
Invest - Other 241,608 236,055 229,871 225,414 221,273 216,479 212,161 206,778 201,210 195,231 192,615 189,210 185,025
Umbrella (lives) 101,448 98,188 92,178
Umbrella schemes 511 503 480
Group (lives) 702,521 707,154 711,051 707,756 711,161 680,754 584,081 562,769 576,450 562,440 578,035 551,219 544,443
Group schemes 2,548 2,581 2,616 2,647 2,663 2,666 2,793 2,844 2,827 2,825 2,797 2,740 2,771
Life NB APE
12 months to 6 months to 12 months to 6 months to 12 months to 6 months to 12 months to 6 months to 12 months to 6 months to 12 months to 6 months to 12 months to
R million June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Individual 2,733 1,440 2,778 1,444 2,663 1,355 2,362 1,204 2,072 1,068 2,126 1,165 2,215
Group 87 23 164 75 175 130 181 64 193 94 160 75 97
Umbrella 383 192 626
Invest - Recurring 1,624 867 1,673 851 1,551 796 1,428 737 1,167 573 1,164 686 1,221
Invest - Single APE1 1,806 867 1,627 778 1,500 708 1,493 782 1,570 744 1,508 671 1,382
Total Life APE 6,633 3,389 6,868 3,148 5,889 2,989 5,463 2,786 5,001 2,478 4,958 2,597 4,915
1 APE shown at 10% of Single premium
Health Members
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
DHMS - Keycare 189,775 204,847 207,934 226,848 225,517 232,988 232,055 234,421 235,841 230,960 232,714 243,046 240,140
DHMS - Non-Keycare 1,169,413 1,154,532 1,152,395 1,147,016 1,149,861 1,142,556 1,135,853 1,118,591 1,111,545 1,099,553 1,111,079 1,108,674 1,110,401
In-House Schemes 370,608 356,504 354,944 321,333 319,813 321,838 318,246 316,973 321,613 321,767 319,974 317,408 316,410
Total 1,729,796 1,715,883 1,715,273 1,695,197 1,695,191 1,697,382 1,686,154 1,669,985 1,668,999 1,652,280 1,663,767 1,669,128 1,666,951
Health Lives
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
DHMS - Keycare 315,406 343,648 350,038 385,906 384,759 398,397 397,595 401,307 404,984 400,108 403,392 420,869 415,436
DHMS - Non-Keycare 2,401,304 2,391,556 2,394,452 2,402,336 2,413,851 2,412,595 2,406,528 2,383,486 2,375,082 2,358,232 2,381,735 2,387,237 2,394,336
In-House Schemes 813,719 800,093 798,933 710,485 707,406 710,427 704,472 699,342 707,293 704,749 698,534 689,688 686,114
Total 3,530,429 3,535,297 3,543,423 3,498,727 3,506,016 3,521,419 3,508,595 3,484,135 3,487,359 3,463,089 3,483,661 3,497,794 3,495,886
Vitality SA
June 2025 December 2024 June 2024 December 2023 June 2023 December 20222 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Total Vitality Health,
Vitality Drive and Vitality
Money programme lives
3,157,572 3,038,785 2,922,347 2,822,972 2,652,877 2,498,048 2,348,834 2,242,401 2,163,411 2,122,453 2,065,868 2,060,011 1,987,237
2 restated to include for LA wellness figures
VitalityHealth Members
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Individual 141,822 141,014 140,400 138,278 135,117 129,568 124,395 117,007 113,189 108,955 105,915 104,997 101,702
SME 349,465 344,320 340,983 327,876 310,624 285,865 263,216 238,540 222,961 211,949 212,305 209,509 201,960
Corporate 131,885 128,241 120,685 112,941 108,191 102,823 99,578 89,881 86,149 80,514 81,124 78,050 70,583
Trust and Cost Plus 18,496 20,198 20,237 16,448 16,339 14,511 8,698 3,944 2,731 2,639 - - -
Total 641,668 633,773 622,305 595,543 570,271 532,767 495,887 449,372 425,030 404,057 399,344 392,556 374,245
VitalityHealth Lives
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Individual 262,888 261,481 260,210 256,527 250,551 238,629 227,684 212,896 204,890 195,996 188,976 186,559 179,811
SME 550,925 545,424 541,111 522,753 496,299 460,442 429,110 395,777 374,179 357,768 356,907 353,763 342,431
Corporate 210,225 202,151 191,015 178,163 171,364 163,120 158,890 148,654 143,905 135,218 135,440 131,991 120,157
Trust and Cost Plus 32,739 35,214 35,163 27,349 26,854 22,673 15,903 6,509 4,066 3,956 - - -
Total 1,056,777 1,044,270 1,027,499 984,792 945,068 884,864 831,587 763,836 727,040 692,938 681,323 672,313 642,399
VitalityLife Policies
June 2025 December 20243 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Policies 781,548 723,213 679,382 646,564 622,451 593,322 565,778 535,281 517,913 493,970 474,890 458,675 434,678
3 December 2024 has been restated
VitalityLife Lives
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Lives4 903,996 852,154 810,050 782,296 764,699 735,137 702,105 669,139 647,020 617,051 594,799 577,965 549,526
4 restated to include unique lives only
Discovery Insure Policies
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Policies 208,192 213,762 214,297 215,297 211,223 214,315 213,453 212,570 202,335 191,936 178,517 169,920 159,171
Discovery Bank
June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022 December 2021 June 2021 December 2020 June 2020 December 2019 June 2019
Primary Clients 1,246,817 1,092,386 958,055 825,069 702,131 581,457 470,220 385,177 331,088 287,183 206,810 61,731 1,476
Total Accounts 2,995,078 2,608,023 2,271,703 1,933,839 1,625,912 1,312,970 1,023,790 793,215 648,546 521,081 357,416 141,660 3,740
2 Membership

-- 2 of 23 --

VALUE OF NEW BUSINESS AT POINT OF SALE VS VALUATION DATE
June 2025
VNB at Point of Sale
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Acquisition Costs and Initial strain (537) (2,937) (1,653) (3,622) (8,749)
Value of In Force 1,632 3,472 2,324 3,775 11,203
Cost of Capital (45) (74) (62) (119) (300)
1,050 461 609 34 2,154
New business contribution to value of in force at valuation date
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Value of In Force 1,597 2,449 2,210 3,404 9,660
Cost of Capital (43) (74) (63) (110) (290)
1,554 2,375 2,147 3,294 9,370
December 2024
VNB at Point of Sale
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Acquisition Costs and Initial strain (264) (1,446) (808) (1,685) (4,203)
Value of In Force 757 1,721 1,015 1,788 5,281
Cost of Capital (21) (36) (26) (42) (125)
472 239 181 61 953
New business contribution to value of in force at valuation date
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Value of In Force 755 1,277 982 1,642 4,656
Cost of Capital (21) (36) (26) (42) (125)
734 1,241 956 1,600 4,531
June 2024
VNB at Point of Sale
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Acquisition Costs and Initial strain (550) (2,833) (1,560) (1,132) (6,075)
Value of In Force 1,653 3,393 2,051 1,074 8,171
Cost of Capital (52) (79) (63) (70) (264)
1,051 481 428 (128) 1,832
New business contribution to value of in force at valuation date
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Value of In Force 1,615 2,454 1,906 909 6,884
Cost of Capital (51) (79) (60) (68) (258)
1,564 2,375 1,846 841 6,626
December 2023
VNB at Point of Sale
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Acquisition Costs and Initial strain (253) (1,452) (754) (635) (3,094)
Value of In Force 659 1,739 999 535 3,932
Cost of Capital (21) (45) (53) (35) (154)
385 242 192 (135) 684
New business contribution to value of in force at valuation date
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Value of In Force 660 1,256 960 513 3,389
Cost of Capital (21) (45) (52) (28) (146)
639 1,211 908 485 3,243
3 Value of New Business

-- 3 of 23 --

EV RECONCILIATION TO INCOME STATEMENT
for the year ended 30 June 2025
R million
Embedded
Value
Earnings
Value of In-
Force
Cost of
required
Capital
Impact on
Income
Statement
Adjustment to
Shareholders
Funds
Statement of
Changes in
Equity
Total profit from new business (at point of sale) 2,154 9,063 (300) (6,609)
- Health and Vitality 1,050 1,521 (45) (426) - -
- Life 461 2,394 (74) (1,859) - -
- VitalityHealth 609 2,021 (62) (1,350) - -
- VitalityLife 34 3,127 (119) (2,974) - -
Profit from existing business
* Expected return 10,878 2,047 (25) 8,856
- Health and Vitality 4,018 591 7 3,420
Expected transfer from VIF to net worth - (3,420) - 3,420
Unwinding of the risk discount rate 4,018 4,011 7 -
- Life 4,662 2,378 - 2,284
Expected transfer from VIF to net worth - (2,284) - 2,284
Unwinding of the risk discount rate 4,662 4,662 - -
- VitalityHealth 1,011 (989) (28) 2,028
Expected transfer from VIF to net worth - (2,028) - 2,028
Unwinding of the risk discount rate 1,011 1,039 (28) -
- VitalityLife 1,187 67 (4) 1,124
Expected transfer from VIF to net worth - (1,124) - 1,124
Unwinding of the risk discount rate 1,187 1,191 (4) -
* Change in methodology and assumptions (404) (4,735) 162 4,169
- Health and Vitality (1,623) (1,659) 36 -
- Life 687 (136) 216 607
- VitalityHealth 487 566 (79) -
- VitalityLife 45 (3,506) (11) 3,562
* Experience variances 2,905 2,461 113 331
- Health and Vitality 251 79 3 169
- Life 1,120 663 - 457
- VitalityHealth 1,435 1,539 119 (223)
- VitalityLife 99 180 (9) (72)
Increase in goodwill and intangibles (382) - - - (382) -
Other initiatives 2,537 - - 2,537 - -
Non-recurring expenses (355) - - (355) - -
Acquisition costs (45) - - (45) - -
Finance costs (3,125) - - (3,125) - -
Other (8) - - (1) (7) -
Foreign Exchange Rate Movements 1,550 1,720 (57) (774) (200) 861
Intangibles (200) - - - (200) -
Other 1,750 1,720 (57) (774) - 861
Return on shareholders' funds 1,669 - - 1,632 - 37
Unrealised gain on investments and realised gain on investments
transferred to income statement 1,136 - - 1,099 - 37
Health and Vitality investment income 84 - - 84 - -
Life investment income 449 - - 449 - -
VitalityHealth investment income - - - - - -
VitalityLife investment income - - - - - -
Amortisation of Intangibles (62) - - (484) 422 -
Amortisation of intangibles from business combinations (62) - - (89) 27 -
Amortisation of systems intangibles - - - (395) 395 -
VitalityHealth and VitalityLife DAC and unemployment reserve - - - 630 (630) -
Reversal of 1 Discovery Place IFRS 16 financial lease accounting - - - (88) 88 -
Life assets under insurance contracts - - - 3,620 (4,736) 1,116
VitalityLife net assets under insurance contracts - - - (439) (349) 788
VitalityHealth Insurance Acquisition Cash Flow (IACF) asset - - - 138 (138) -
VitalityHealth FinRe - - - 631 (631) -
Equity settled share based payment mark-to-market adjustment - - - (435) 435 -
Embedded value earnings 17,312 10,556 (107) 9,558 (5,497) 2,802
Adjustment to Shareholders' Funds:
Change in: *
VitalityHealth Insurance Acquisition Cash Flow (IACF) asset (769)
Intangibles & Goodwill (166)
Life net assets under insurance contracts (4,736)
VitalityLife net assets under insurance contracts (349)
1 DP IFRS 16 financial lease accounting 88
Equity settled share based payment mark-to-market adjustment 435
* The total change in the net assets under insurance contracts consists of the change in the Negative Rand Reserve (NRR), which is zeroised in the embedded value. The change in the NRR is split
between the Income Statement and the change in Other Comprehensive Income (OCI) which flows through the Statement of Changes in Equity (SOCIE).
4 EV recon

-- 4 of 23 --

EV BUILD-UP PER ENTITY
for the year ended 30 June 2025
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Other Total
Value of in-force business at 30 June 2024 26,914 35,813 13,904 14,435 - 91,066
Expected return (in-force business) 3,938 4,531 925 1,081 - 10,475
Release of profits (in-force business) (3,420) (2,284) (2,028) (1,124) - (8,856)
Value of new business 1,587 3,398 2,262 3,656 - 10,903
Expected return (new business) 80 131 86 106 - 403
Release of profits (new business) (111) (1,078) (303) (648) - (2,140)
Experience variances 82 663 1,658 171 - 2,574
Methodology changes (1,623) 80 487 (3,517) - (4,573)
Other - 1 878 784 - 1,663
Value of in-force business at 30 June 2025 27,447 41,255 17,869 14,944 - 101,515
Shareholders’ funds per Balance Sheet 1,686 32,242 10,636 5,002 16,133 65,699
Adjustment to shareholders' funds - (21,333) (5,120) (11,670) (2,537) (40,660)
Embedded value at 30 June 2025 29,133 52,164 23,385 8,276 13,596 126,554
5 EV Buildup per Entity

-- 5 of 23 --

COMPONENTS OF ASSETS UNDER INSURANCE CONTRACTS AND ADJUSTMENT TO
SHAREHOLDERS' FUNDS ON PUBLISHED BASIS
R million June 2025 June 2024
1. Assets under insurance contracts
Discovery Life positive liabilities not netted off with negative liabilities: 571 627
Discovery Life long term reserves in respect of policies with net negative liabilities: (31,656) (27,448)
Working capital 210 148
Discovery Life liability for incurred claims (LIC) 7,873 7,619
Total Assets under insurance contracts: (23,002) (19,054)
2. Negative liabilites not included under assets under insurance contracts
Negative reserve in respect of Invest business (7,617) (7,011)
DAC and DRL in respect of Invest business (811) (769)
(8,428) (7,779)
3. Components to be zeroised based on the Method of Distributable Cashflows:
Discovery Life long term reserves in respect of policies with net negative liabilities: (31,656) (27,448)
Liabilities under reinsurance contracts* 432 258
Negative reserve in respect of Invest business (7,617) (7,011)
DAC and DRL in respect of Invest business (811) (769)
Adjust for reduction on Deferred Tax Liability as a result of reduction in earnings 6,705 6,165
Liabilities off set against Negative reserve before zeroisation 11,614 12,208
(21,333) (16,597)
* This amount is the liability under reinsurance contracts, net of CSM, in respect of the portion of the gross assets under insurance contracts zeroised based on the
method of distributable cashflows.
4. Other adjustments to published Shareholders' funds
VitalityLife net assets under insurance contracts (11,663) (11,314)
VitalityHealth Insurance Acquisition Cash Flow (IACF) asset (5,120) (4,351)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (7) (8)
Goodwill (3,012) (2,855)
Intangible assets (net of deferred tax) relating to the acquisition of Standard Life Healthcare and the Prudential Assurance
Company joint venture (813) (803)
Net preference share capital (779) (779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 1,550 1,462
Equity settled share based payment mark-to-market adjustment 517 82
Adjustment to Shareholders' funds from published basis (40,660) (35,163)
For June 2024, the “Adjustments to Shareholders’ funds from published basis” have been restated as a result of prior period errors - refer to section D1.1 for more detail. The restatements do not affect the
Group Embedded Value at 30 June 2024 as they relate to Life net assets under insurance contracts, which are eliminated on a consolidated embedded value basis.
6 EV Adjustment to SH funds

-- 6 of 23 --

RECONCILIATION TO THE REQUIRED CAPITAL
for the year ended 30 June 2025
R million Health and Vitality Life and Invest VitalityHealth VitalityLife Total
Opening - 30 June 2024 1,238 27,935 4,138 11,299 44,610
- -
- Methodology and Basis Changes - (809) - (834) (1,643)
- Expected release on in-force at start of period 0 (507) (145) (431) (1,083)
- Impact of new business written 119 916 429 2,331 3,795
- Other changes* (71) 1,814 125 44 1,912
- Exchange rate movements - - 214 641 855
Change in Required Capital 48 1,414 623 1,751 3,836
Closing - 30 June 2025 1,286 29,349 4,761 13,050 48,446
*This line includes, amongst other things, the impact of rebasing the yield curve as part of the opening to closing reconciliation of required capital. This component
of the expected yield curve unwind is shown separately from the expected release for information purposes only.
7 Recon of Required Capital

-- 7 of 23 --

BREAKDOWN OF INVEST AND UMBRELLA ASSETS UNDER ADMINISTRATION
R million Invest Umbrella
December 2021 127,632
June 2022 121,737
December 2022 130,830
June 2023 140,378
December 2023 144,810
June 2024 154,653 17,074
December 2024 166,915 18,196
June 2025 178,744 22,487
8 Invest and Umbrella AUA

-- 8 of 23 --

SA SA SA SA SA UK UK ALL OTHER SEGMENT IFRS
R million HEALTH LIFE INVEST INSURE BANK HEALTH LIFE SEGMENTS TOTAL TOTAL
30 June 2025
Income statement
Insurance revenue 518 19 149 4 560 6 217 - 19 124 8 050 95 57 713 - 57 713
- Contracts measured under the General measurement model/Variable fee approach - 15 419 4 560 - - - 8 050 - 28 029 - 28 029
- Contracts measured under Premium allocation approach 518 3 730 - 6 217 - 19 124 - 95 29 684 - 29 684
Insurance service expenses ( 362) (15 512) (2 676) (5 499) - (17 292) (7 595) ( 92) (49 028) - (49 028)
- Claims and benefits ( 216) (11 375) ( 608) (3 000) - (11 300) (3 681) ( 51) (30 231) - (30 231)
- Insurance service expense and other ( 66) (1 795) (1 057) (1 597) - (3 981) ( 879) ( 37) (9 412) - (9 412)
- Insurance acquisition cash flows ( 80) (2 342) (1 011) ( 902) - (2 011) (3 035) ( 4) (9 385) - (9 385)
Tax specific to policyholder tax funds - - ( 97) - - - - - ( 97) 97 -
Insurance service result (pre-reinsurance) 156 3 637 1 787 718 - 1 832 455 3 8 588 97 8 685
Net expenses from reinsurance contracts ( 1) (1 021) - ( 112) - ( 3) ( 165) ( 4) (1 306) - (1 306)
- Reinsurance expense ( 2) (3 838) - ( 130) - ( 5) (8 839) ( 34) (12 848) - (12 848)
- Insurance claims recovered from reinsurers 1 2 817 - 18 - 2 8 674 30 11 542 - 11 542
Insurance service result 155 2 616 1 787 606 - 1 829 290 ( 1) 7 282 97 7 379
Net financial result from insurance finance income and expense - 2 466 (15 831) ( 20) - - 417 - (12 968) ( 120) (13 088)
- Net finance income/(expense) from insurance contracts - 2 590 (15 831) ( 20) - - 716 - (12 545) ( 120) (12 665)
- Net finance expense from reinsurance contracts - ( 124) - - - - ( 299) - ( 423) - ( 423)
Investment income using the effective interest rate method 11 15 75 268 - 179 81 17 646 352 998
Net fair value gains on financial instruments at fair value through profit or loss 29 3 537 17 058 11 52 70 - - 20 757 5 061 25 818
Fair value adjustments to liabilities under investment contracts - (2 961) ( 905) - - - - - (3 866) 56 (3 810)
Third party interest: fair value adjustments to liabilities under investment contracts - - - - - - - - - (4 394) (4 394)
Intersegment funding - 362 ( 362) - - - - - - - -
Other losses on financial instruments - - - - ( 9) - - - ( 9) - ( 9)
Net insurance and investment results 195 6 035 1 822 865 43 2 078 788 16 11 842 1 052 12 894
Fee income from administration businesses 9 766 188 1 260 - - 35 - 3 185 14 434 ( 108) 14 326
Vitality income - - - - - 31 267 5 575 5 873 ( 551) 5 322
Net banking fee and commission income - - - - 1 373 - - ( 77) 1 296 399 1 695
- Banking fee and commission income - - - - 2 238 - - - 2 238 - 2 238
- Banking fee and commission expense - - - - ( 865) - - ( 77) ( 942) 399 ( 543)
Net banking interest and similar income - - - - 965 - - - 965 1 966
- Banking interest and similar income using the effective interest rate - - - - 2 203 - - - 2 203 - 2 203
- Banking interest and similar expense using the effective interest rate - - - - (1 238) - - - (1 238) 1 (1 237)
Other income 1 838 119 1 79 69 19 - 14 591 16 716 (14 884) 1 832
Non-insurance revenue and income 11 604 307 1 261 79 2 407 85 267 23 274 39 284 (15 143) 24 141
Net income 11 799 6 342 3 083 944 2 450 2 163 1 055 23 290 51 126 (14 091) 37 035
Non-insurance acquisition costs - - ( 395) - - - - ( 294) ( 689) 305 ( 384)
Expected credit losses - - - - ( 279) - - - ( 279) - ( 279)
Marketing and administration expenses (7 540) ( 817) ( 701) ( 213) (2 239) ( 975) ( 424) (23 305) (36 214) 14 449 (21 765)
Share of net profits from equity-accounted investments - - - 86 - - 6 1 174 1 266 ( 51) 1 215
Normalised profit/(loss) from operations 4 259 5 525 1 987 817 ( 68) 1 188 637 865 15 210 612 15 822
Investment income earned on shareholder investments and cash 98 31 13 7 - - - 203 352 ( 352) -
Intercompany investment income - - - - - - - 1 351 1 351 (1 351) -
Net fair value gains on financial instruments at fair value through profit or loss - 51 54 - - - - - 105 ( 105) -
Loss from dilution of equity accounted investments - - - ( 32) - - - - ( 32) - ( 32)
Impairment of goodwill ( 20) - - - - - - - ( 20) - ( 20)
Amortisation of intangibles from business combinations - - - ( 51) - - - ( 71) ( 122) 122 -
Market rentals related to Head Office building adjusted for finance costs and depreciation - - - - - - - ( 72) ( 72) 72 -
Restructuring costs - - - - - - - ( 80) ( 80) 80 -
Interest expenses on borrowings and lease liabilities ( 2) ( 1) - - - ( 18) ( 201) (1 588) (1 810) ( 277) (2 087)
Intercompany finance expenses on borrowings ( 447) - - - - - ( 444) ( 460) (1 351) 1 351 -
Foreign exchange (losses)/gains ( 5) ( 14) ( 5) - - - 1 ( 13) ( 36) - ( 36)
Profit/(loss) before income tax 3 883 5 592 2 049 741 ( 68) 1 170 ( 7) 135 13 495 152 13 647
Income tax expense (1 046) (1 508) ( 793) ( 216) 25 ( 311) ( 62) ( 26) (3 937) ( 152) (4 089)
Profit/(loss) for the year 2 837 4 084 1 256 525 ( 43) 859 ( 69) 109 9 558 - 9 558
Profit attributable to:
Ordinary shareholders 2 843 4 084 1 256 525 ( 43) 859 ( 69) 16 9 471 - 9 471
Preference shareholders - - - - - - - 93 93 - 93
Non-controlling interest ( 6) - - - - - - - ( 6) - ( 6)
Material items of expenses
Depreciation and amortisation ( 174) ( 1) ( 24) ( 1) ( 368) - ( 58) (1 273) (1 899)
Derecognition of intangible assets and property and equipment - ( 43) - ( 52) - - ( 1) ( 45) ( 141)
Impairment of intangible assets and property and equipment ( 20) ( 28) - ( 18) - ( 79) - - ( 145)
Staff costs (3 038) ( 284) ( 262) ( 95) ( 984) - - (8 062) (12 725)
Other expenses (4 308) ( 461) ( 415) ( 47) ( 887) ( 896) ( 365) (13 925) (21 304)
(7 540) ( 817) ( 701) ( 213) (2 239) ( 975) ( 424) (23 305) (36 214)
For notes to the Segment Information, please refer to section 1.1 in the Audited Results and cash dividend declaration for the year ended 30 June 2025.
Segment information
IFRS REPORTING
ADJUSTMENTS

-- 9 of 23 --

VIF, APE AND VNB SPLIT BETWEEN LIFE AND INVEST
R million June 2025 December 2024 June 2024 December 2023 June 2023 December 2022 June 2022
VIF1
Life 27,910 27,082 24,138 22,859 22,244 23,133 22,059
Invest 13,346 12,715 11,675 10,429 9,393 9,521 8,505
APE2
Life 735 355 804 426 823 463 837
Invest 2,535 1,234 2,411 1,150 2,142 1,033 2,158
VNB1
Life 113 94 225 136 162 169 364
Invest 349 145 256 106 267 160 341
1 These VIF and VNB numbers are after allowing for the Cost of required Capital.
2 APE is the Annual Premium Income (or Annual Premium Equivalent in the case of Single Premium Investment business) in relation to New Business only, and excludes
any addition to Existing Business premiums arising from servicing increases and ACIs.
Discovery Retirement Optimiser (DRO) product moved from Life to Invest in line with disclosures for December 2016 and later periods.
10 Results split Life and Invest

-- 10 of 23 --

Group Shareholder Free Cash Movement
R millions FY2025 H1 FY2025 FY2024 H1 FY2024 FY2023
Cash Generated from In-Force Before Financing and Tax 17,655 8,319 14,617 7,567 14,425
New Business Net of External Financing (6,791) (3,506) (6,823) (3,528) (7,243)
Tax Paid (1,867) (758) (1,522) (792) (1,839)
Operating Cash Flow 8,997 4,055 6,272 3,247 5,343
New Initiatives (615) (727) (1,025) (776) (1,671)
Business Development and Other (1,243) (595) (1,580) (864) (1,274)
Finance Cost Paid (1,691) (899) (1,566) (802) (1,501)
Dividends Paid (1,708) (1,073) (1,270) (783) (69)
Financing and Matching Initiatives (539) (236) (496) (332) 166
Transactions with Borrowers (Excl. Finance Costs) (1,572) (491) 1,130 (80) (597)
Movement in Shareholder Free Cash 1,629 35 1,465 (390) 397
Remove ordinary dividends paid in period 1,614 1,026 1,179 740 -
Add ordinary dividends payable in respect of period (1,954) (588) (1,465) (439) (740)
Movement in Shareholder Free Cash – Dividend Accrual Basis (1) 1,289 473 1,179 (89) (343)
Movement in Shareholder Free Cash - Excl Transactions with Borrowers and Financing
and Matching Initiatives 3,740 762 831 22 828
Operating Cash Flow 8,997 4,055 6,272 3,247 5,343
IFRS Normalised Operating Profit net of Tax Expense (2) 11,734 5,529 9,650 5,161 8,406
Cash Conversion Ratio (2) 77% 73% 65% 72% 64%
Group Shareholder Free Cash Movement - Reconciliation to Profit for the Period
R millions FY2025 H1 FY2025 FY2024 (3) H1 FY2024 (3) FY2023
Profit for the period 9,558 4,329 7,549 3,361 6,572
Reverse non-cash profit items:
Share of net (profits)/losses from equity accounted investments (1,266) (425) (1,031) (302) (561)
Losses/(gains) from dilution of equity accounted investments 32 26 (22) - 5
Depreciation and amortisation 2,177 1,074 2,160 1,040 1,972
Impairment of intangible assets 131 21 45 4 61
Deferred acquisition costs (Excl. Invest DAC and exchange rate movements) - - - - (42)
Movement in contract assets (359) (462) (640) (252) 52
Amortisation of intangibles from business combinations - - - - 56
Non cash impact of Vitality Health DAC (510) (217) (411) (206) (753)
Non-cash fair value gains on financial assets (21) (47) (87) (56) (214)
Non-cash forex gains / losses 20 - - - 9
Bank interest income incurred to cash (152) (277) - - -
Other non-cash adjustments to profit 54 (22) (151) (65) (178)
Adjustments from IFRS to EV ANW:
Increase in Negative Reserves and Invest DAC (Net of tax) (3,181) (1,487) (4,733) (1,784) (5,393)
Exchange rate movements on Vitality Life Negative Reserves 481 206 (385) (137) 1,900
Other adjustments to arrive at EV ANW (279) 404 1,644 137 196
Incurred to Cash basis:
- Rent Paid (580) (329) (511) (286) (328)
- Finance Costs Paid (2,877) (1,494) (2,603) (802) (1,501)
- Finance Costs Accrued 3,324 1,711 3,097 1,025 1,941
- Taxation paid (1,867) (758) (1,522) (792) (1,839)
- Taxation Accrued 2,049 654 1,093 810 1,495
Investing Activities:
Purchase of property and equipment (294) (120) (414) (246) (551)
Proceeds from disposal of property and equipment 3 3 28 - 2
Purchase of intangible assets (1,682) (875) (1,789) (800) (1,760)
Increase in investment in associate 463 (11) 287 (176) (75)
Acquisition of business net of cash required (316) - - - (3)
Cash proceeds from CMT transaction - (304) - - -
Financing Activities:
Increase in borrowings 3,264 1,765 2,005 500 7,441
Repayment of borrowings (4,836) (2,257) (874) (580) (8,038)
Dividends paid to ordinary shareholders (1,614) (1,026) (1,179) (739) -
Dividends paid to preference shareholders (93) (47) (91) (44) (69)
Movement in Shareholder Free Cash 1,629 35 1,465 (390) 397
Notes
"Movement in Shareholder Free Cash" is an estimate of shareholder free cashflow. Life and Invest and VitalityLife are included based on the change in the Adjusted Net Worth in the Embedded Value. Changes in
working capital are not allowed for in the estimate.
1) This view of the movement in shareholder free cash flow aligns the dividend paid to the period against which the cash flow was generated to fund it. For the year ended 30 June 2025, the interim declared dividend
of R588m, per the interim financial results, and the final declared dividend of R1 366m, per the annual financial results, are used as the total dividend accrued in respect of the twelve-month period.
2) Cash conversion is calculated as Operating Cash Flow per the Group shareholder free cash movement, divided by Normalised profit from operations (IFRS total) net of Income tax expense (IFRS total) per A.1
Segment Information. "IFRS Normalised Operating Profit net of Tax Expense" and "Cash Conversion" for H1 FY2024 and FY2024 have been restated as a result of prior period errors related to movements in Life net
assets under insurance contracts - refer to section D1.1 for more detail.
3) Related to note 2 above, "Profit for the period" for H1 FY2024 and FY2024 has been restated. The restatements do not affect the net Movement in Shareholder Free Cash Flow for those periods as they relate to
movements in Life net assets under insurance contracts, which are non-cash flow movements. The offsetting adjustment has been included in "Increase in Negative Reserves and Invest DAC (Net of tax)" in the build-
up above.

-- 11 of 23 --

Reconciliation of operating profit to normalised operating profit
for the year ended 30 June 2025
Group Group
R million
Year
ended
June 2025
Year
ended
June 2024 % change
Operating profit 14,587 11,390 28%
Share of net profits from equity accounted investments 1,215 975
Impairment of goodwill 20 -
Normalised profit from operations per Segment information (IFRS total) 15,822 12,365 28%
Normalised profit adjustments ( 612) ( 604)
Investment income earned on shareholder investments and cash ( 352) ( 318)
Difference between market related rental and depreciation and finance costs (Head office) ( 205) ( 181)
Tax specific to policyholder tax funds ( 152) ( 96)
Net fair value gains on financial assets at fair value through profit or loss ( 105) ( 162)
Amortisation of intangibles from business combinations 122 105
Restructuring costs 80 48
Normalised profit from operations 15,210 11,761 29%
12 Op Profit recon

-- 12 of 23 --

Discovery Bank additional performance metrics
for the six months ended 30 June 2025
2025 H2 2025 H1 2024 H2 2024 H1 2023 H2 2023 H1
Profitability and Efficiency
Retail Net Interest Margin (NIM)* 8.85% 9.65% 10.19% 10.06% 9.53% 9.37%
Asset Quality
Non-Performing Loan (NPL) Ratio 4.79% 4.92% 5.41% 5.84% 5.02% 4.16%
Capital Adequacy
Common Equity Tier 1 (CET1) Ratio 16.31% 16.67% 17.63% 17.07% 16.82% 16.47%
Liquidity
Loan-to-Deposit Ratio (LDR) 39.37% 37.05% 35.72% 34.48% 36.08% 23.46%
*Excludes interest on bonds

-- 13 of 23 --

NAV PER ENTITY
for the year ended June 2025
Covered businesses June 2025
NAV before adjustment to shareholder funds
Health and Vitality 1,686
Life and Invest 32,242
VitalityHealth 10,636
VitalityLife 5,002
Non-covered businesses
Bank, including DCS intangible asset and goodwill 8,516
Insure 2,705
PAHI 7,331
CMT 1,338
Limited (10,517)
Other 6,760
Total NAV 65,699

-- 14 of 23 --



-- 15 of 23 --

PAHI performance metrics
RMB million (100% PAHI unless otherwise stated) June 2025 June 2024 %change 2025 2024 %change
New business PAHI Own Licence 4,807 3,842 25% 3,064 2,251 36%
New business PAHI Own Licence (25%) 1,201 960 25% 766 563 36%
PAHI Own Licence written premium 18,824 16,118 17% 11,372 9,583 19%
PAHI Own Licence earned premium 17,807 14,747 21% 9,521 7,617 25%
PAHI profit before investment income and gains 1,398 1,470 -14% 1,092 1,114 -2%
PAHI investment income and gains 1,146 621 84% 547 419 30%
PAHI pre-tax profit 2,544 2,092 22% 1,638 1,533 7%
PAHI profit before income and gains (25%) 636 523 22% 409 383 7%
Investible assets 26,247 23,328 13%
Full years (DSY reporting cycle) Half-years (calendar year)

-- 16 of 23 --

Value generation of business under IFRS17 - Discovery Life and Invest

-- 17 of 23 --

Value generation of business under IFRS17 - Vitality Life

-- 18 of 23 --

Normalised Return on Equity
FY2025 FY2024 FY2023
EARNINGS
Net profit - attributable to: 9,558 7,549 6,961
- Ordinary shareholders 9,471 7,468 6,899 A
- Preference shareholders 93 91 69
- Non-controlling interest (6) (10) (7)
Earnings adjustments for ordinary shareholders 310 43 (110) C=B-A
Normalised headline earnings 9,781 7,511 6,789 B
EQUITY
Opening total equity 54,451 47,242 38,787
- Insurance Finance Reserve (4,832) (6,312) (3,483)
- Perpetual preference share capital 779 779 779
- Non-controlling interest - 4 5
- Other equity 58,504 52,771 41,486 D
Adjusted opening equity 58,504 52,771 41,486 E=D
Closing total equity 65,699 54,451 47,242
- Insurance Finance Reserve (2,928) (4,832) (6,312)
- Perpetual preference share capital 779 779 779
- Non-controlling interest (5) - 4
- Other equity 67,854 58,504 52,771 F
Adjusted closing equity 67,854 58,504 52,771 G=F
Normalised adjusted closing equity 68,164 58,547 52,661 H=G+C
Average normalised equity 63,334 55,659 47,073 I=(H+E)/2
RETURN ON EQUITY Full-year
Normalised return on equity (annualised) 15.4% 13.5% 14.4% =B/I

-- 19 of 23 --

Analyst Q&A
Discovery Life
• Can you explain the SA Life CSM reduction, as compared to positive EV impact, and the impact
of policy alterations
Please see the slides titled ‘Value generation of business under IFRS 17’, ‘Non-financial risk
variances and basis changes’ and the commentary in this additional analyst information.
CSM changes should be considered together with RA and OCI as a store of value and in the
broader context of the total change in store of value over the period, including new business,
interest accretion and release to profit. Combined these increased the store of value by c.R900
million or 4%.
Reflecting on the slides: The R3.2 billion CSM & RA impact (net of reinsurance) due to variances
and basis and methodology changes are reported at initial recognition interest rates rather than
current rates, and so an OCI component is created directly related to these CSM movements.
Allowing for this, the combined FY25 GMM store of value change due to variances and basis and
methodology changes is a reduction of R2.3 billion (gross of tax). The overall EV experience
variances and assumptions changes for the period, excluding economic movements, was positive
in the period at a gain of R404m. This is a function of additional movements which do not impact
the GMM store of value, largely related to the strong positive claims experience reflected directly
in earnings, and other differences between IFRS17 and EV. The slides titled ‘Non-financial risk
variances and basis changes’ illustrates the link from the applicable EV experience variances and
methodology and assumption changes to the store of value changes (CSM + RA + OCI).
Policy alterations were the largest negative contributor to experience variances in the period.
This has been a key focus for management with multiple initiatives having been phased in to
improve alteration experience.
• What is the impact of the CSM reduction on earnings
Under IFRS17, the release of CSM to earnings occurs after the impact of non-economic
experience and basis changes. As a result, the negative CSM impact was already incurred in the
earnings for FY2025 and it did not have a significant impact on the life earnings.
• How sustainable is the mortality & morbidity experience going forward?
Claims experience over a single year alone cannot be considered credible enough to guide future
experience. However, the positive experience in FY25 has a beneficial impact on the five-year
average, excluding COVID-19 related claims, which is a positive indication. The positive
experience was across both Individual and Group Life, mortality and morbidity.

-- 20 of 23 --

• Please explain the reduction in the Individual Life new business margin
New business does have a notable fixed overhead cost base, making the margin responsive to
volume and mix changes. Individual Life’s new business margin reduced from 5.0% to 3.8%
largely due to lower new business volumes. The underlying profitability of policies, normalising
for expenses, remain strong.
The business continues to focus on quality of new business, increasing sales volumes and
appropriate expense management to improve the margin. Included in this are the recently
relaunched Will and Trust offering, distribution initiatives as well as future offering products in
collaboration with Discovery Bank.
• Please expand on 2H EV lapse experience in Life & Invest and Health & Vitality. Also for the
positive Mortality & Morbidity changes.
Lapse improvements in H2 are driven by the Life and Invest businesses. Invest experience was
particularly strong across most main product lines. The claims experience improvement was
fairly broad across all benefits on Individual and Group Life. The claims assumption change
relates to a review of projected claims reserve level (and therefore projected interest on reserves)
in the Group Life business. The assumption change also includes minor methodology refinements
in Individual Life.
• Could you remind us what the amortisation rate for both RA and CSM?
The releases or amortisations are calculated using coverage units which represent updated
expected future sums assured and remain stable year-on-year. For both RA and CSM, they can be
calculated as:
Release Rate = Release / (Opening Balance + New Business Added + Interest Accreted +
Changes in Estimates Related to Future Service)
Alternatively:
Release Rate = Release / (Closing Balance – Release)
Using notes 2.5.1 and 2.9.1 in the AFS to calculate Life GMM release rates net of reinsurance:
CSM Release Rate: FY25 = 6.3%; FY24 = 5.7%.
RA Release Rate: FY25 = 6.9%; FY24 = 6.8%.
• How important is bancassurance in addressing new business pressure (both SA Life and SA
Insure). How long will this take to have a meaningful impact? Could you compete effectively
with Capitec in the middle to mass market?
This is a key focus for the business over the short to medium term, with significant opportunity
given the substantial ‘new to Discovery’ client base introduced by Discovery Bank.

-- 21 of 23 --

Discovery Bank
• Why are the number of discovery bank clients at 1.2 and accounts at 3 million respectively?
Does this mean on average everyone has 2.5 accounts? Why would they need more than one
account? Any clarification would be greatly appreciated.
On average, clients hold about 2.4 accounts. Beyond their primary transaction and credit card
accounts, clients often take up additional savings and lending products that suit their specific
banking needs. These are recorded as individual accounts for clients.
• What is the potential for the Discovery Bank home loan book over the next five years? Are you
considering launching any new banking products in 2026?
Our home loan book has shown strong early momentum, growing to over R2bn since its launch in
May 2024. Currently, the majority of this comes from clients switching from other banks, and is
further supported by our ability to offer personalised interest rates that can be reduced through
managing your money well and product integration. Over the next five years, we see significant
potential as we increase focus on both switches and new originations, particularly as interest
rates normalise.
In March, the Bank launched a range of new products and features to make banking more
personal, more intelligent, more secure and more rewarding. These included the launch of
Discovery AI, and security features that protect our clients and their finances. In addition, we
recently launched personal loans via the Bank app, further expanding our lending suite.
As part of Discovery Group’s annual September launch cycle, we consistently introduce new
products and enhancements across our businesses. The Bank will announce its 2026 innovations
during the upcoming cycle. As the Bank grows, we will remain focused on launching solutions
that will enable us to target new client segments and cater for a wider range of client needs.

-- 22 of 23 --

VitalityHealth
• For VitalityHealth, what is the outlook for inflation? What is your expectation/need for further
rate increases to meet your margin target?
Medical inflation tends to be higher than consumer inflation rates, as with all markets. Following
the recent rebasing of premiums to reflect increased claims utilisation levels, no further
significant rate increases are foreseen at this time. The business will continue to ensure that
responses to future utilisation and claims inflation changes are appropriate and proportionate.
VitalityLife
• Can you comment on the negative VNB margin in VitalityLife in the second half of 2025 vs the
strong positive result in the first half?
The result in the second half was primarily influenced by a change in basis, which materially
impacted reported outcomes for the period.
• Do you have an ambition for the VitalityLife VNB margin or are your comfortable with 0.2%?
We continue to target a new business internal rate of return (IRR) of risk-free + 5%. The VNB
margin is expected to continuing growing as the expense base increases by less than the growth
in new business levels, reducing the cost per policy.
Vitality Network
• Why does VN revenue growth continue to lag client growth? How long before these become
aligned? Do you expect margin expansion in FY26 and thereafter?
Performance-based fees have increased in line with the growth in Intellectual Property (IP) sales,
with the non-performance fees growing at a lower level; Despite ongoing investment alongside
AIA, we expect margins to improve in the near term, particularly since there is now the
opportunity for new European partners to grow revenue with limited impact on the expense
base; We remain confident in achieving our target margin of 50% by 2029.

-- 23 of 23 --